Update on male circumcision: prevention success and challenges ahead
- PMID: 18510888
- PMCID: PMC2711844
- DOI: 10.1007/s11908-008-0040-9
Update on male circumcision: prevention success and challenges ahead
Abstract
This article reviews the findings of three trials of male circumcision for HIV prevention, with emphasis on the public health impact, cultural and safety concerns, implications for women, and the challenges of roll out. Three randomized trials in Africa demonstrated that adult male circumcision reduces HIV acquisition by 50% to 60%. As circumcision provides only partial protection, higher risk behaviors could nullify circumcision's effect. Additionally, circumcision among HIV-infected men does not directly reduce male-to-female HIV transmission among discordant couples, according to the results of a recent Ugandan study. The roll-out or full-scale implementation requires committed expansion into existing HIV prevention programs. Efforts should include attention to safety, implications for women, and risk compensation. Rapid, careful establishment of circumcision services is essential to optimize HIV prevention in countries with the highest prevalence.
Conflict of interest statement
Disclosures
The authors have reported no potential conflicts of interest relevant to this article.
Figures
References
-
- Gray R, Azire J, Serwadda D, et al. Male circumcision and the risk of sexually transmitted infections and HIV in Rakai, Uganda. AIDS. 2004;18:2428–2430. - PubMed
-
- Hodges FM. The antimasturbation crusade in antebellum American medicine. J Sex Med. 2005;2:722–731. - PubMed
-
- American Academy of Pediatrics. Report of the Task Force on Circumcision. Pediatrics. 1989;84:388–391. - PubMed
-
-
Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298. Report of the South African circumcision trial prematurely discontinued in 2005 for approximately 60% reduced risk of HIV acquisition. When controlling for behavioral and genital symptoms, the protective effect was 61% (95% CI, 34%–77%)
-
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials